Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Incyte Earns $25M Novartis Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Incyte Earns $25M Novartis Milestone

EMA issues positive opinion for Jakavi for polycythemia vera

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Incyte Corp has earned a $25 million milestone payment from Novartis, triggered by the EMA’s positive opinion for Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea.
 
Under the collaboration and license agreement signed in 2009, Novartis has exclusive development and commercialization rights to ruxolitinib outside of the U.S. for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Incyte markets ruxolitinib as Jakafi in the U.S.
 
“We are very pleased with the progress that Novartis has made in the global development and commercialization of Jakavi,” said Hervé Hoppenot, president and chief executive officer of Incyte. “This recommendation for approval in Europe, the second indication for Jakavi and many months ahead of schedule, is further evidence that our innovative scientific advances can offer significant benefit to patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics